Covis Group Acquires AMAG Pharmaceuticals

Azurity Pharmaceuticals Acquires Covis Pharma

March 14, 2025

Pharmaceuticals

Azurity Pharmaceuticals has completed its acquisition of Covis Group S.à r.l. (Covis Pharma) from existing investors, making Covis a wholly owned subsidiary of Azurity. The deal expands Azurity's therapeutic portfolio across multiple complex dosage forms and broadens its global footprint, with the combined company serving 50+ countries and employing more than 800 colleagues.

Apollo Funds to Acquire Covis Pharma from Cerberus

February 6, 2020

Pharmaceuticals

Funds managed by affiliates of Apollo Global Management have agreed to acquire Covis Pharma BV from an affiliate of Cerberus Capital Management. Terms were not disclosed; the transaction is expected to close by the end of Q1 2020 and aims to accelerate Covis's global expansion and build out its respiratory and specialty pharma franchises.

ATHAGORAS Group Acquires CSO Pharma Consulting GmbH

November 18, 2024

Healthcare Services

ATHAGORAS Group has acquired CSO Pharma Consulting GmbH to expand and internationalize its pharmacovigilance, medical affairs, quality management and GDP consulting capabilities across the pharma and healthcare sectors. The deal adds a specialized provider of PV and regulatory support to ATHAGORAS' life‑sciences services platform while CSO retains focus on organic growth and continuity for clients and employees.

Pfizer Acquires Seagen for $43 Billion

December 14, 2023

Biotechnology

Pfizer completed the acquisition of Seagen, acquiring all outstanding Seagen common stock for $229 per share in cash in a transaction valued at approximately $43 billion. The deal adds Seagen's ADC technology, four in-line oncology medicines and a large early-stage pipeline to Pfizer's oncology portfolio, expanding Pfizer's capabilities and doubling its oncology pipeline.

Cinven Acquires Majority Stake in BioAgilytix; Cobepa Reinvests

December 20, 2021

Healthcare Services

International private equity firm Cinven has agreed to acquire a majority stake in BioAgilytix through a recapitalization, with current investor Cobepa remaining a significant minority investor. GHO Capital has realised its investment and will exit; the transaction will provide funding to support BioAgilytix’s international expansion, capacity and capability investments, and buy-and-build strategy in large-molecule bioanalytical services. BioAgilytix is headquartered in Durham, North Carolina and employs about 870 staff across the United States, Europe and Australia.

Merck to Acquire Imago BioSciences, Inc.

November 21, 2022

Pharmaceuticals

Merck has agreed to acquire clinical-stage biopharmaceutical company Imago BioSciences for $36.00 per share, representing an approximate equity value of $1.35 billion. The acquisition adds Imago's lead LSD1 inhibitor bomedemstat to Merck's hematology pipeline and is expected to close after a tender offer and customary regulatory clearances in early 2023.